Nanoencapsulation of Zataria multiflora Essential Oil Containing Linalool Reduced Antibiofilm Resistance against Multidrug-resistant Clinical Strains

Abstract

Background: The rise in antimicrobial resistance, caused by the production of biofilms by bacteria, is a significant concern in the field of healthcare. Nanoemulsion technology presents itself as a viable alternative in the quest to circumvent antibiotic resistance in pathogenic bacteria. Objective: The aim of this research was to form a sustainable nanoemulsion from Z. multiflora, and evaluate its antibacterial and anti-biofilm activities against the clinical isolates of Pseudomonas aeruginosa, Proteus mirabilis, and Staphylococcus aureus. Materials and Methods: Bioactive compounds of the oil were identified using GC-MS. Zataria multiflora essential oil (ZMEO) nanoemulsion was formulated as a water-dispersible nanoemulsion with a diameter of 184.88 ± 1.18 nm. The antibacterial and antibiofilm activities of the essential oil in both pure and nanoemulsion forms were assessed against pathogenic bacteria causing hospital-acquired infections using minimal inhibitory concentrations (MICs) and the microtiter method, respectively. Results: The main constituents were found to be linalool (78.66 %), carvacrol (14.25 %), and α- pinene (4.53%). Neither ZMEO nor the emulsified ZMEO showed any antimicrobial activity. However, ZMEO exhibited a low inhibition of biofilm formation by P. mirabilis, S. aureus, and P. aeruginosa. The most promising finding was that when the emulsified ZMEO was present at a concentration of 750 μg/mL, it significantly reduced biofilm formation by the aforementioned bacteria to 39.68% ± 2.62, 56.54% ± 3.35, and 59.60% ± 2.88, respectively. This result suggests that ZMEO nanoemulsion has the potential to effectively disrupt persistent biofilms and enhance the penetration of antimicrobial agents into the biofilm matrix. Conclusion: In conclusion, the study provides evidence supporting the use of ZMEO nanoemulsion as a potential treatment option for combating biofilm-related infections caused by Pseudomonas aeruginosa, Proteus mirabilis, and Staphylococcus aureus. Further research is warranted to explore the practical application of the proposed essential oil in clinical settings.